阿斯利康今年预计还将公布超过20项三期试验结果，且还有100多项三期临床试验正在进行中，包括多种创新技术疗法。 2月10日，阿斯利康公布2025年第四季度及全年财报。2025年，阿斯利康全球总营收达587.39亿美元，同比增长8%，其中阿斯利康中国 2025年总营收达66.54亿美元，同比增长4%，占总收入比约11%，生物制药、肿瘤、罕见病三大业务领域均实现增长。 阿斯利康预测，2026年利润和销售将继续增长，这主要得益于癌症治疗和新药的需求。去年第四季度，阿斯利康肿瘤药业务增长20% 至70.3亿美元，但心血管业务受仿制药竞争影响下跌6%至30.5亿美元。 阿斯利康近期还调整了上市架构，普通股于2月2日在纽约证券交易所开始交易。 阿斯利康的目标是到2030年，年度销售额达到800亿美元，这一目标的实现将通过开发新药物和进行投资来实现。公司计划到2030年推 出20款全球创新药。 为此，阿斯利康正在推动在美国和中国的扩张。上个月，阿斯利康宣布从现在到2030年将在中国投资超1000亿元人民币，以扩大在药 品生产与研发领域的布局。这也是阿斯利康史上最大规模对华投资计划。 过去几年来，阿斯利康不断加大与中国领先生 ...

| AZN 阿斯利康 | | | | --- | --- | --- | | 188 010 L -5.020 -2.60% | | 收盘价 02/09 16:00 美东 | | 192.200↑ 4.190 +2.23% | | 盘前价 02/10 04:05 美东 | | 三 24 S m 9 目 ♥ 自选 | | ● 快捷交易 | | 最高价 192.760 | 开盘价 191.800 | 成交量 303.08万 | | 最低价 187.060 | 昨收价 193.030 | 成交额 5.74亿 | | 平均价 189.232 | 市盈率 IM 31.23 | 总市值 2915.93亿(…) | | 振 幅 2.95% | 市密率(静) 41.78 | 总股本 15.51亿 | | 换手率 0.20% | 市净率 6.354 | 流通值 2902.05亿 | | 52周景高 193.970 | 委 比 -- | 流通股 15.44亿 | | 52周最低 121.634 | 量 比 0.93 | 色 手 1股 | | 历史最高 193.970 | 股息TTM 3.133 | | | 历史最低 10.525 ...

Core Insights - AstraZeneca reported a core earnings per share of $2.12 for Q4, with total revenue increasing by 2% to $15.5 billion, aligning with consensus expectations of $2.12 billion and $15.4 billion [1] - The company forecasts steady profit growth by 2026, with sales growth expected to slow down, focusing on the demand for its cancer drugs while increasing R&D investments and addressing geopolitical pressures and patent expirations [1] - AstraZeneca aims for total revenue growth in the mid-single digits and core profit growth in the low double digits by 2026, despite the impact of a major diabetes drug's patent expiration [1] Revenue Breakdown - Q4 cancer drug sales rose by 20% to $7.03 billion, while cardiovascular drug revenue fell by 6% to $3.05 billion, partly due to competition from generics, including diabetes and heart failure drug Farxiga [1] - The company is on track to achieve its ambitious goal of $80 billion in annual sales by 2030 under the leadership of CEO Pascal Soriot, driven by new drugs and investments despite unstable U.S. tariffs and healthcare policies [1] Future Plans - AstraZeneca reiterated its goal of achieving $80 billion in revenue by the end of the decade and plans to announce results from up to 20 advanced clinical trials this year [4] - Upcoming new drugs will target obesity, lung cancer, and chronic obstructive pulmonary disease [4] - The company plans to increase its annual dividend by approximately 3% to $3.30, reflecting confidence in its long-term plans [4] Market Strategies - AstraZeneca has taken significant steps to achieve growth in the U.S. and China, including a $50 billion manufacturing agreement in the U.S. and a $15 billion investment in China [4] - The experimental obesity drug, elecoglipron, is entering the final stages of clinical trials [4] - Despite potential impacts from U.S. drug pricing agreements, the company believes it can withstand the effects of these transactions [4]

Investment Rating - The investment rating for the industry is "Positive" and the rating has been maintained [1] Core Insights - The pharmaceutical and biotechnology industry index experienced a decline of 3.17%, ranking 22nd among 31 primary industries, underperforming the CSI 300 index which fell by 1.25% [6][17] - The valuation of the pharmaceutical and biotechnology industry as of February 6, 2026, is a PE (TTM overall method, excluding negative values) of 29.57x, down from 30.31x in the previous period, indicating a downward trend below the average [6][22] - The top three sub-industries in terms of PE (TTM overall method, excluding negative values) are vaccines (46.30x), hospitals (43.34x), and medical consumables (37.71x), while the median is 32.64x, with pharmaceutical distribution having the lowest valuation at 14.88x [22] Industry Trends - The focus in the global pharmaceutical market is on GLP-1 targets, with Eli Lilly's Tirzepatide establishing a leading position in the metabolic disease field due to its clinical value and commercialization performance [9] - The collaboration model between multinational pharmaceutical companies and Chinese biopharmaceutical firms is evolving towards "platform capabilities + multi-project combinations," highlighting the long-term strategic value of underlying innovative capabilities such as sustained delivery technology and peptide R&D platforms [9] - The investment logic in the industry is shifting from single blockbuster products to platform-based, matrixed approaches, and key supply chain segments [9] Investment Recommendations - Focus on innovative pharmaceutical companies with "core technology platforms + diversified pipelines," as their ability to derive multiple values from platforms and achieve cross-border collaboration milestones will be a key advantage [9] - Pay attention to industry chain segments benefiting from drug long-acting and oral trends, including complex formulation processes, high-end delivery technologies, and related peptide CDMO fields [9] - In the context of strong global R&D and production demand, peptide CXO companies that are active in cross-border collaborations, have balanced customer structures, and possess solid compliance systems will continue to share in the industry's high prosperity dividends [9]

Group 1 - The core viewpoint of the articles indicates that AstraZeneca expects a double-digit percentage growth in adjusted earnings per share by 2026, driven by strong sales in its oncology drug business, which will offset the impact of patent expirations on core diabetes drugs [1] - AstraZeneca's fourth-quarter profits and revenues met expectations, with the company forecasting mid-to-high single-digit revenue growth for the year, similar to the 8% increase in 2025, allowing room for potential upward revisions later in the year [1][2] - The company is accelerating its entry into the weight loss drug market, having recently signed a collaboration agreement with China’s CSPC Pharmaceutical Group worth up to $18.5 billion, which includes access to CSPC's long-acting peptide technology platform for developing next-generation weight loss therapies [1] Group 2 - AstraZeneca's self-developed oral GLP-1 drug, elecoglipron, has entered late-stage clinical trials, becoming a key candidate in its obesity treatment pipeline [1] - The company has confidence in managing pricing impacts and is focused on achieving its long-term revenue target of $80 billion by 2030, with several new drugs in clinical development being critical for maintaining growth momentum [2] - Under CEO Pascal Soriot's leadership, AstraZeneca has established a leading position in oncology and is the second-largest listed company on the London Stock Exchange, with key clinical data for new drugs targeting diseases like lung cancer and COPD expected to be released this year [3]

格隆汇2月10日｜英国制药巨头阿斯利康公布2025年业绩，全年总营收达到587.39亿美元，按固定汇率 计同比增长8%，主要得益于肿瘤、心血管和罕见病业务板块的增长；其中，产品销售额为555.73亿美 元，同比增长9%；核心每股收益为9.16美元，同比增长11%。就2025年第四季度而言，总营收为155.03 亿美元，同比增长2%；核心每股收益为2.12美元，同比下滑2%。 展望2026年，阿斯利康预计总营收将实现中高个位数百分比的增长，核心每股收益将实现低两位数百分 比的增长。 阿斯利康首席执行官Pascal Soriot表示："2025年，公司在各个治疗领域都取得了强劲的商业表现，研发 管线进展顺利。公司公布了16项积极的三期临床试验结果，目前拥有16款重磅药物。展望2026年，公司 将继续保持增长势头，期待今年公布超过20项三期临床试验的结果。"公司宣布派发第二次中期股息， 每股2.17美元；2025年总股息增长3%至每股3.2美元。 ...

Core Insights - The company anticipates revenue growth for 2026 to be in the mid-to-high single-digit percentage range, indicating a positive outlook for future sales performance [1] - Core earnings per share are expected to increase by a low double-digit percentage, reflecting strong profitability expectations [1]

Core Insights - The pharmaceutical giant reported profits that met expectations and revenue that slightly exceeded forecasts on Tuesday [1] Financial Performance - Profit was in line with market expectations [1] - Revenue slightly beat forecasts [1]

来源：滚动播报 阿斯利康：预计全年总收入将实现中至高个位数百分比的增长。 ...

AstraZeneca on Tuesday forecast profit and sales growth in 2026, betting on demand for its cancer and cardiovascular treatments while the drugmaker pursues massive expansion in the U.S. and China. ...